-
Fan Wang (Guest)
Ph.D, Prof.
-
Principal Investigator Laboratory of Protein and Peptide Drugs, IBP Professor, Peking University Health Science Center
Research Interests: Molecular imaging and molecular probe
Email: wangfan@bjmu.edu.cn
Tel: 010-82802871
Address: 15 Datun Road, Chaoyang District, Beijing, 100101, China
Chinese personal homepage
- Biography
-
1984 - 1988 B.S, Jilin University
1988 - 1991 M.S, Jilin University
1994 - 1997 Ph.D, China Institute of Atomic Energy
1998 - 2000 Postdoctoral Fellow, Oak Ridge National Laboratory; Washington University School of Medicine
1991 - 2008 Assistant Professor, Associate Professor, and Professor, China Institute of Atomic Energy
2001 - Professor, Peking University Health Science Center
2013 - Professor and Principal Investigator (Guest), Institute of Biophysics, Chinese Academy of Sciences
- Awards
-
2011 National Outstanding Youth, NSFC
2008 Berson-Yalow Award, Society of Nuclear Medicine, USA
- Membership in Academies & Societies
-
Chairman, Chinese Society for Molecular Imaging
Editorial Board, Bioconjugate Chemistry, Nuclear Science and Techniques
Associate Editor, Biophysics Reports
Director of International Society of Radiopharmaceutical Sciences
- Research Interests
-
Molecular imaging, a rapid growing research field in the last decade, provides a powerful tool for the noninvasive characterization and quantification of biological processes in living subjects at the cellular and molecular levels. Central to molecular imaging is the development of imaging probes. Our research interests focus on the design and development of a series of novel molecular probes targeted to the key biomarkers during disease progress. By optimizing in preclinical animal models and clinical trials, these novel probes are expected to play pivotal roles in early disease detection and staging, as well as real-time response monitoring towards personalized therapy.
- Grants
- Selected Publications
-
1. Ma X, Yao M, Shi J, Li X, Gao Y, Luo Q, Hou R, Liang X* andWang F*, High Intensity Focused Ultrasound-Responsive and Ultra-stable Cerasomal Perfluorocarbon Nanodroplets for Alleviating Tumor Multidrug Resistance and Epithelial-Mesenchymal Transition,ACS Nano, 2020, DOI: 10.1021/acsnano.0c07287.
2. Gao H#, Wu Y#, Shi J#, Zhang X, Liu T, Hu B, Jia B, Liu Z, Wan Y,Wang F*. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.J Immunother Cancer2020;0:e001156.
3. Gao S#, Jia B#, Feng G#, Dong C#, Du H, Bai L, Zhong Q, Ma Q*, Zeng M*,Wang F*. First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer.Sig Transduct Target Ther. 2020, 5:147.
4. Wu Y#, Li L#, Wang Z, Shi J, Hu Z, Gao S, Miao W, Ma Q, Dong C*,Wang F*. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe (99m)Tc-HYNIC-H10F,Eur. J. Nucl. Med. Mol. Imaging, 2020. 47, 2613-2623.
5. Yao M, Ma X, Zhang X, Shi L, Liu T, Liang X, Zhao H, Li X, Li L, Gao H, Jia B*,Wang F*. Lectin-mediated pH-sensitive Doxorubicin Prodrug for Pre-targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.Theranostics. 2019, 9(3):747-760.
6. Ma, X.; Li, X.; Shi, J.; Yao, M.; Zhang, X.; Hou, R.; Shao, N.; Luo, Q.; Gao, Y.; Du, S.; Liang, X.*;Wang, F*. Host-Guest Polypyrrole Nanocomplex for Three-Stimuli-Responsive Drug Delivery and Imaging-Guided Chemo-Photothermal Synergetic Therapy of Refractory Thyroid Cancer.Advanced healthcare materials2019, 8, e1900661.
7. Gao H, Luo C, Yang G, Du S, Li X, Zhao H, Shi J*, andWang F*. Improved in Vivo Targeting Capability and Pharmacokinetics of99mTc-Labeled isoDGR by Dimerization and Albumin-Binding for Glioma Imaging.Bioconjug Chem. 2019 Jul 17;30(7):2038-2048.
8. Jia B#, Zhang X#, Wang B, Chen M, Lv F, Wang S *, andWang F*. Dual-Modal Probe Based on Polythiophene Derivative for Pre- and Intraoperative Mapping of Lymph Nodes by SPECT/Optical Imaging.ACS Appl Mater Interfaces2018, 10, 6646-6651.
9. Liang X*, Fang L, Li X, Zhang X,Wang F*. Activatable near infrared dye conjugated hyaluronic acid based nanoparticles as a targeted theranostic agent for enhanced fluorescence/CT/photoacoustic imaging guided photothermal therapy.Biomaterials. 2017, 132:72-84.
10. Li, L.#; Wu, Y.#; Wang, Z.; Jia, B.; Hu, Z.; Dong, C.;Wang, F*. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models.J Nucl Med. 2017, 58, 821-826.
11. Yu X, Wu Y, Liu H, Gao L, Sun X, Zhang C, Shi J, Zhao H, Jia B, Liu Z,Wang F*.Small-Animal SPECT/CT of the Progression and Recovery of Rat Liver Fibrosis by Using an Integrin alphavbeta3-targeting Radiotracer.Radiology,2016.5.01, 279(2):502~512.
12. Liu Z*, Liu H, Ma T, Sun X, Shi J, Jia B, Sun Y, Zhan J, Zhang H, Zhu Z,Wang F*.Integrin αvβ6-targeted SPECT imaging for pancreatic cancer detection.J Nucl Med.2014, 55(6):989-994.
13. Liu Z*, Sun X, Liu H, Ma T, Shi J, Jia B, Zhao H,Wang F*.Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models.J Nucl Med.2014, 55(5):818-23.
14. Shi J, Fan D, Dong C, Liu H, Jia B, Zhao H, Jin X, Liu Z, Li F,Wang F*.Anti-tumor Effect of Integrin Targeted177Lu-3PRGD2 and Combined Therapy with Endostar.Theranostics.2014, 4(3):256-266.
15. Zhu Z, Weibing Miao W, Li Q, Dai H, Ma Q, Wang F, Yang A, Jia B, Jing X, Sha L, Shi J, Liu Z, Zhao Z,Wang F*, Li F*.99mTc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: a Multi-Center Study.J Nucl Med.2012, 53(5):716-722.
16. Liu Z, Liu Y, Jia B, Zhao H, Jin X, Li F, Chen X,Wang F*. Epidermal Growth Factor Receptor-Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using90Y-Labeled Fully Human Antibody Panitumumab.Mol Cancer Ther. 2010, 9(8):2297-2308.
-
Clinical Trial Approval
-
Patents
China Food and Drug Administration, a class 1 new drug clinical trial approval (drug name:99mTc-3PRGD2injection), approval number: 2018L02484. Currently in clinical phase III trials.
15 Patents: ZL200810239036.X; ZL200910077039.2; ZL2014100840659; ZL201310304250.X; ZL201410084837.9; ZL201611095315.4; ZL2017103346344; ZL2017103341374; ZL201710713055.0; ZL201611095338.5; ZL201711113966.6; ZL201811055196.9; ZL201910441556.7; ZL201910048535.9; ZL201910049263.4.
(From Fan Wang, November 24, 2020)